This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
BD (BDX) & BioGX Submit EUA to Speed Up Coronavirus Screening
by Zacks Equity Research
BD (BDX) expects screening to ramp up by 1,000 per day once authorized.
Thermo Fisher (TMO) Gets EUA From FDA for COVID-19 Testing
by Zacks Equity Research
The emergency authorization of this test has made Thermo Fisher (TMO) a key player in the field of coronavirus diagnosis.
Here's Why You Should Hold on to Thermo Fisher (TMO) for Now
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher (TMO) on the strong Q4 performance in the majority of its segments.
Thermo Fisher (TMO) to Buy Molecular Diagnostics Major QIAGEN
by Zacks Equity Research
Thermo Fisher (TMO) expects QIAGEN's strong molecular diagnostics presence to complement its specialty diagnostics capabilities.
Why Is Thermo Fisher (TMO) Down 9.1% Since Last Earnings Report?
by Zacks Equity Research
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: Abbott Laboratories, Myriad Genetics, LabCorp, QIAGEN and Thermo Fisher
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott Laboratories, Myriad Genetics, LabCorp, QIAGEN and Thermo Fisher
Genetic Test Gets Okayed by FDA: 4 Stocks to Keep an Eye On
by Sriparna Ghosal
The growth in genetic testing market can be attributed to factors like rise in incidence of genetic disorders, cancer and technological breakthroughs.
Why Western Digital (WDC) Might be Well Poised for a Surge
by Zacks Equity Research
Western Digital (WDC) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
3 Medical Product Stocks Likely to Beat This Earnings Season
by Trina Mukherjee
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
Sonoco (SON) Meets Q4 Earnings Estimates
by Zacks Equity Research
Sonoco (SON) delivered earnings and revenue surprises of 0.00% and 0.35%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stock Feb 6 Earnings Roster: BDX, CAH & More
by Zacks Equity Research
Despite the ongoing US-China trade war, increased focus on innovation is likely to have driven performance of medical products players' quarterly performance.
Thermo Fisher (TMO) Q4 Earnings Top, Organic Growth Solid
by Zacks Equity Research
We are upbeat that two of Thermo Fisher's (TMO) four business segments deliver strong year-over-year revenue growth in Q4.
Thermo Fisher Scientific (TMO) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of 0.28% and 0.67%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Why Thermo Fisher Scientific (TMO) Might Surprise This Earnings Season
by Zacks Equity Research
Thermo Fisher Scientific (TMO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Medical Products' Jan 30 Earnings Roster: TMO, EW & More
by Zacks Equity Research
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
What's in Store for Thermo Fisher (TMO) in Q4 Earnings?
by Zacks Equity Research
Strength in segments is expected to get reflected in Thermo Fisher's (TMO) fourth-quarter and 2019 top-line numbers.
Thermo Fisher Scientific (TMO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Thermo Fisher Hits New 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Thermo Fisher (TMO) is optimistic about maintaining its growth momentum on several recent developments.
Why Thermo Fisher (TMO) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Is Thermo Fisher Scientific (TMO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (TMO) Outperforming Other Medical Stocks This Year?
Thermo Fisher Rides on New Product Suite, Currency Woes Stay
by Zacks Equity Research
Thermo Fisher Scientific (TMO) recently unveils a product suite comprising the TSQ Altis, Quantis MD mass spectrometers and Vanquish MD HPLC.
Here's Why You Should Retain Pacific Biosciences Stock Now
by Zacks Equity Research
Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.
Here's Why You Should Hold on to Thermo Fisher Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher (TMO) on its stellar segmental performance.
The Zacks Analyst Blog Highlights: QUALCOMM, NVIDIA, Charter, Microsoft and Thermo Fisher Scientific
by Zacks Equity Research
The Zacks Analyst Blog Highlights: QUALCOMM, NVIDIA, Charter, Microsoft and Thermo Fisher Scientific
5 Corporate Giants That Popped in 2019 and Have Upside Left
by Nalak Das
A stable U.S. economy, a partial trade deal with China, possible solution of Brexit and easy monetary policy of the Fed are likely to sustain Wall Street's rally in 2020.